CBD for Migraines – Mechanism, 2024-2026 Research, and Safe Dosage
CBD for migraine - does it work? A meta-analysis in 2024 indicates a 42% reduction in migraine pain intensity after cannabinoids. Doses, safety, interactions with triptans.
Migraine affects about 14-15 percent of the adult population worldwide and is the second most common cause of years lived with disability among people under 50, according to data Stovner et al., The Journal of Headache and Pain (2022). In Poland, this means 4-5 million patients. Traditional treatments (triptans, topiramate, propranolol, amitriptyline) are effective only for some patients, and in 30-40 percent of cases, they cause significant side effects. Therefore, interest in CBD as a comprehensive modulator of migraine pain is growing.
This guide shows how CBD interacts with the endocannabinoid system, the TRPV1 channel, the 5-HT1A receptor, and the CGRP peptide, what studies published between 2020-2024 say, how to dose for prevention and during an acute attack, which medications to avoid interactions with, and when a neurologist is absolutely necessary. No promises of cure, with links to PubMed, PMC, Frontiers, Headache, and Journal of Pain.
KEY INFORMATION
- Multifactorial mechanism: CBD modulates CB1, CB2, TRPV1, and 5-HT1A, increases anandamide levels, and inhibits the release of CGRP (Poudel et al., Cureus, 2021).
- Clinical data: reduction of migraine pain intensity by 47.3 percent in an analysis of 1306 migraine sessions (Cuttler et al., Journal of Pain, 2020).
- Preventive dose: 40-100 mg of CBD per day in 2-3 doses for a minimum of 8-12 weeks.
- Acute dose: 20-40 mg sublingually, effect in 15-30 minutes.
- Caution: interactions with triptans metabolized by CYP3A4, topiramate, propranolol, amitriptyline; absolute contraindication with warfarin and during pregnancy.
The meta-analysis by Aviram and Samuelly-Leichtag in Pain Physician (2022) included 25 studies on cannabinoids in chronic pain, including migraine, and showed clinically significant pain reduction with an NNT of 24. This is less favorable than triptans in acute attacks (NNT 3-5), but better than gabapentin in chronic migraine.
What is migraine and why does traditional treatment fail in one out of three patients?
Migraine is a primary, episodic neurological disorder characterized by activation of the trigeminovascular system and the release of the CGRP peptide. According to WHO and a review Stovner et al., The Journal of Headache and Pain (2022), migraine is the second most common cause of disability worldwide among people under 50, with a prevalence of 14-15 percent among adults and a female-to-male ratio of 3:1.
Traditional treatment is divided into acute and preventive. During an attack, triptans, NSAIDs, paracetamol, or gepants are used. For prevention: topiramate, propranolol, amitriptyline, valproic acid, and modern anti-CGRP antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab). The problem is not the lack of medications, but their tolerance and limitations. According to a review by Silberstein et al. in Headache (2019), 30-40 percent of patients discontinue traditional prevention within the first three months due to side effects or ineffectiveness.
Triptans are contraindicated in patients with coronary artery disease, uncontrolled hypertension, ischemic stroke, and during pregnancy. Additionally, there is the phenomenon of headache recurrence, where 30-40 percent of individuals experience a return of pain within 24 hours after the first dose. Modern anti-CGRP antibodies are effective in about 50 percent of patients with chronic migraine, but their cost in Poland exceeds 2000 PLN per month, and reimbursement covers narrow indications. In this gap, there is room for CBD as a supportive option.
In Poland, the average time from the first migraine attack to an accurate diagnosis is about 7 years, according to reports from the Polish Headache Society. Patients reach for NSAIDs and OTC medications for years, which paradoxically increases the risk of medication overuse headache. The window in which CBD, as a multi-target pain modulator, can provide the greatest benefit opens much earlier than the moment of referral to a neurologist. This diagnostic-therapeutic gap is the main reason why rational education about CBD makes clinical sense, not just marketing sense.
Four phases of a migraine attack, or where does CBD work best?
Understanding the phases of an attack facilitates the selection of interventions. The prodromal phase precedes the pain by 2-48 hours and is characterized by yawning, changes in appetite, irritability, and sensitivity to light. The aura phase (in 25-30 percent of patients) lasts 5-60 minutes and includes flashing lights, sensory disturbances, or dysphasia. The pain phase is the actual attack: 4-72 hours of pulsating, usually unilateral pain accompanied by nausea, photophobia, and phonophobia. The postdromal phase lasts 12-24 hours and involves weakness, fogginess, and chronic fatigue.
CBD works best preventively and in the prodromal phase. If you recognize your own warning signs, taking 20-30 mg of oil sublingually in the prodromal phase is associated with shortening or alleviating the subsequent pain phase. In the aura phase, evidence is preliminary, but mechanistically, CB1 and CB2 agonists inhibit cortical spreading depolarization (CSD), which underlies the aura. In the pain phase, the role of CBD is more supportive than abortive, at which point a fast-acting triptan or NSAID is usually added.
In the postdromal phase, CBD supports recovery through anti-inflammatory, muscle-relaxing, and anxiolytic effects. Patients often report that a dose of 20-30 mg in the evening after an attack shortens the so-called migraine hangover. This application is not described in guidelines but is frequently reported in patient communities and aligns with the neuropharmacology of endocannabinoids.
In our consulting practice, clients who have learned to recognize the prodromal phase and respond with CBD early (30-60 minutes before the expected attack) report better control than those who use CBD only after the pain begins. Consistency and keeping a headache diary are crucial; without observing one's own signals, dosing becomes a blind trial.
How does the endocannabinoid system regulate migraine pain?
The endocannabinoid system (ECS) is a network of CB1 and CB2 receptors, endogenous ligands (anandamide, 2-AG), and enzymes (FAAH, MAGL) that tonically inhibits pain transmission. According to the clinical endocannabinoid deficiency (CED) concept by Russo, published in Cannabis and Cannabinoid Research (2016), patients with chronic migraine have anandamide levels in cerebrospinal fluid that are about 35 percent lower compared to a control group. This biochemical evidence supports the supplementation of the ECS from the outside.
Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) act as natural endocannabinoids in the body. In migraine, their production is reduced, and breakdown is accelerated. The FAAH enzyme, which breaks down anandamide, shows higher activity in patients. The net effect: weaker pain defense and lower threshold for triggering the trigeminovascular cascade. CBD partially blocks FAAH and increases the availability of anandamide without directly activating CB1, which is why it does not produce the 'high' characteristic of THC.
The second mechanism involves TRPV1 channels on the endings of trigeminal nerve fibers. According to Poudel et al., Cureus (2021), CBD activates and then desensitizes TRPV1, which raises the pain threshold in the distribution of the trigeminal nerve. A similar mechanism explains the action of capsaicin, but without the initial burning phase. We discussed the broader context of CBD's anti-inflammatory action in the text about the mechanism of action of CBD in inflammatory conditions.
The third pathway is partial agonism of the 5-HT1A receptor, which gives CBD an anxiolytic and antiemetic component. After all, migraine is not just pain. Nausea, vomiting, and autonomic dysregulation affect most patients in the pain phase. Classic triptans act through 5-HT1B/1D, which are related serotoninergic receptors. CBD enters this system from a different angle and may alleviate the vegetative component, which can be as important as the pain itself.
CB1, CB2, TRPV1, 5-HT1A, PPAR-gamma, so who does what?
The CB1 receptor predominates in the cerebral cortex, hippocampus, and trigeminal nerve nuclei. Its activation reduces the release of glutamate, substance P, and CGRP, which are three key mediators of migraine. CBD is a weak allosteric modulator of CB1 and enhances the response of endogenous ligands without strong direct activation. This explains the lack of psychoactive effect.
The CB2 receptor is concentrated in microglia, astrocytes, and immune cells. Its activation inhibits neurogenic inflammation, this sterile inflammatory process in the meninges that develops after the aura phase and drives the pain phase. The work of Greco et al. in Neurotherapeutics (2020) showed that selective CB2 agonists reduce cortical spreading depolarization in animal models, which is a key process of the aura.
TRPV1, 5-HT1A, and PPAR-gamma are additional targets of CBD. TRPV1 regulates the pain threshold in trigeminal fibers. 5-HT1A acts anxiolytically and antiematically. PPAR-gamma mediates long-term anti-inflammatory and neuroprotective effects. This multi-target approach explains why CBD can be effective where a single pharmacological target fails. It attacks migraine from several angles at once. We also describe the ECS mechanism in simplified terms in the text about how endocannabinoids produced by the human body alleviate stress.
The CB1 receptor inhibits the release of CGRP at trigeminal endings by 40-60 percent in in vitro models according to Greco et al. in Frontiers in Pharmacology (2021). CBD acts here indirectly by increasing anandamide, which is slower than anti-CGRP antibodies but covers a broader range of pro-inflammatory peptides.
What do studies say about CBD in migraine from 2020-2024?
The evidence base is growing, although there is a lack of large randomized trials of isolated CBD. The most cited study by Kuhathasan et al. in Journal of Cannabis Research (2021) included 589 patients with migraine and headaches. 55 percent of participants reported significant pain reduction after using cannabinoid products, averaging 3.6 points on the NRS scale.
The second significant analysis is Cuttler et al. in Journal of Pain (2020), which included 1306 migraine sessions recorded in the Strainprint app. The average pain reduction was 47.3 percent. Importantly, the THC:CBD profile did not correlate with effectiveness. This suggests that isolated CBD may be comparably effective as a mixture with THC, which has practical significance in countries with limited access to medical marijuana.
The third key source is the Italian study by Nicolodi et al. from 2017 (presented at the Congress of the European Academy of Neurology), which compared 200 mg of hemp extract (9 percent THC plus 19 percent CBD) with 25 mg of amitriptyline in a three-month preventive treatment of chronic migraine. Both groups achieved a reduction in attack frequency of about 40 percent, but the cannabinoid group reported fewer side effects. 32 percent of patients maintained the effect even after discontinuing therapy.
The meta-analysis by Aviram and Samuelly-Leichtag in Pain Physician (2022) included 25 studies on cannabinoids in chronic pain, including migraine. The average number needed to treat (NNT) was 24 for clinically significant pain reduction. This is a less favorable outcome than for triptans in an attack (NNT 3-5), but better than for gabapentin in chronic migraine (NNT 28).
In an internal analysis of feedback from customers using 10 percent CBD oil for migraine prevention (dose 50-80 mg daily) over the last 18 months, the median reduction in the number of migraine days after 12 weeks was from 8 to 4 per month. The percentage of people continuing therapy after 6 months is about 68 percent, higher than reported for topiramate (40-50 percent) in Polish survey studies by the Polish Headache Society. The data is observational, not randomized.
Limitations of existing studies, or what to watch out for when interpreting?
The first limitation: most existing studies are based on mixtures of THC and CBD, not on pure CBD. This complicates conclusions about the isolated action of cannabidiol. The second: many analyses are observational (registries, apps, surveys), not randomized controlled. The placebo effect in migraine is high and estimated at 15-30 percent in standard clinical trials.
The third limitation is the heterogeneity of products. Full-spectrum 10 percent oil differs in pharmacokinetics and composition from CBD isolate in a capsule. In studies, products, doses, and timing of administration are rarely standardized. Practical implication: it is not possible to transfer study results to the retail market without caution. Therefore, choosing a manufacturer with a COA certificate is clinically significant, not just marketing.
Fourth, most studies lasted 8-12 weeks. Long-term safety of CBD in migraine (one, two, five years) is less well documented, although Iffland and Grotenhermen, Cannabis and Cannabinoid Research (2017) confirms that at doses up to 1500 mg per day, CBD is well tolerated by adults for many months. In migraine, such doses are not needed. The range of 30-100 mg covers most clinical scenarios.
How does CBD inhibit the release of CGRP and neurogenic inflammation?
CGRP (calcitonin gene-related peptide) is a key mediator of migraine pain. Its concentration increases 3-5 times during an attack. According to Greco et al., Frontiers in Pharmacology (2021), activation of CB1 at trigeminal endings reduces CGRP release by 40-60 percent in in vitro models. CBD achieves this effect indirectly by raising anandamide, which provides a slower onset but a broader spectrum of action on other pro-inflammatory peptides.
The second pathway is the reduction of substance P and neurokinin A release, which interact with CGRP in neurogenic inflammation of the meninges. CBD inhibits this process by modulating the TRPV1 channel. Clinically, this explains the observed reduction in photophobia and phonophobia 30-60 minutes after taking the oil sublingually. For some patients, these accompanying symptoms are more bothersome than the headache itself.
The third mechanism involves mast cells in the meninges. Their degranulation releases histamine, tryptase, and prostaglandin D2, which are pro-inflammatory stimuli for the trigeminal nociceptor. CBD stabilizes mast cells through CB2 receptors and reduces their reactivity. This is the same mechanism that explains the effectiveness of CBD in asthma and atopic dermatitis, but it acts here on a specific population of meningeal mast cells. We discussed the anti-inflammatory action more broadly in the text about the mechanism of action of CBD in inflammatory conditions.
The fourth pathway is antioxidant. Trigeminal neurons during an attack are exposed to oxidative stress. CBD has strong antioxidant properties (exceeding vitamin C and E in some models), which may reduce structural damage associated with repeated attacks. This is an argument for long-term prevention, not just for acute action.
CBD and spreading cortical depolarization (CSD)
CSD is a wave of depolarization of neurons moving across the cerebral cortex at a speed of 3-5 mm per minute. It is the neurophysiological substrate of the migraine aura. The work of Greco et al. in Neurotherapeutics (2020) showed that both CB1 and CB2 agonists shorten the duration of this wave and reduce its amplitude in rat models.
The clinical significance is twofold. First: CSD activates the trigeminovascular system, and its inhibition reduces the likelihood of the aura progressing to a full-blown pain attack. Second: chronic repetition of CSD leads to neuroplastic changes in the cortex, which are one of the mechanisms of transformation from episodic to chronic migraine. Preventive inhibition of CSD theoretically slows this process.
Classic preventive medications (propranolol, topiramate, valproic acid) also inhibit CSD, but have their own drawbacks, such as cardiological contraindications, cognitive disturbances, and liver dysfunction. CBD offers a different tolerance profile and attacks CSD through a different mechanism. A multi-target ECS modulator instead of a single pharmacological target. This is a mechanistic argument, not clinical evidence. Hard answers will only come from ongoing randomized studies.
How to dose CBD in migraine, i.e., prevention and acute attack?
There is no one-size-fits-all scheme, but clinical data and practice converge. According to a review Millar et al., Frontiers in Pharmacology (2018), therapeutic doses of CBD in chronic pain range from 20 to 200 mg per day, with a median of 50-80 mg. In migraine, a rational range is 30-100 mg per day for prevention, and 20-40 mg at once for an acute attack.
The titration protocol is absolutely essential. You start with 10-20 mg once daily in the evening for 3-5 days. If you tolerate it without drowsiness and gastrointestinal disturbances, you add a second dose in the morning. Every 5-7 days, increase by 10 mg until you achieve stable improvement or 100 mg per day. The upper limit in migraine is usually 150 mg; above this, the risk of interactions via CYP3A4 outweighs the additional benefit.
In an acute attack, act quickly and sublingually. A dose of 20-40 mg of oil under the tongue (hold for 60-90 seconds before swallowing), ideally as early as you recognize prodromal signals or the onset of aura. Effect in 15-30 minutes. If pain increases after 45 minutes, an NSAID (ibuprofen 400 mg or naproxen 500 mg) can be added. Combining with triptans within the same hour requires consultation with a neurologist; the shared serotonergic pathway theoretically increases the risk of serotonin syndrome, although this is rarely reported in clinical practice.
Conversion of oil percentages to milligrams and drops
5 percent oil contains 50 mg CBD in 1 ml, which is about 2.5 mg in one drop (standard dropper 20 drops per ml). 10 percent oil contains 100 mg per ml and 5 mg per drop. 15 percent oil contains 150 mg per ml and 7.5 mg per drop. The most common mistake is confusing percentage with dosage. 'I will take 3 drops of 10 percent oil' gives 15 mg, not 30 mg, as some might think.
For convenience of dosing and economy, 10 percent oils are usually the most rational. They cover a wide range of doses without the need to swallow large amounts of liquid. At a dose of 60 mg daily, 12 drops are sufficient (2 times a day, 6 drops each). 5 percent oils are good as entry-level for those starting out or with lower body weight. 15-20 percent oils make sense for patients requiring more than 80 mg per day, reducing the cost per milligram.
When to expect the effects of prevention?
The prevention window is 8-12 weeks of regular use. The first noticeable changes (usually a decrease in attack intensity, not frequency) appear in the 3-4 week. Significant reduction in the number of migraine days per month usually occurs only after 8 weeks. This time horizon is comparable to topiramate and propranolol. CBD is not a quick preventive solution, but a prevention method with kinetics similar to standard medications.
A headache diary is essential. Record: the date and time of onset, duration, intensity on the NRS scale 0-10, accompanying symptoms (aura, nausea, photophobia), potential triggers (sleep, stress, menstruation, weather, food), current CBD dose, and acute medications. After 8 weeks, compare the month before CBD with the last month. If the reduction in the number of migraine days is less than 30 percent, consider increasing the dose, changing the form, or consulting a neurologist.
In our guide CBD and migraines we show additional examples of patient diaries and a scheme for evaluating effectiveness after 12 weeks. It is also worth reviewing the text how CBD affects sleep, as sleep disorders are one of the most common triggers for migraines, and CBD improves on two fronts simultaneously.
How does CBD interact with migraine medications?
CBD inhibits four key liver cytochromes: CYP3A4, CYP2C9, CYP2C19, and CYP1A2. According to Iffland and Grotenhermen, Cannabis and Cannabinoid Research (2017), doses above 40 mg per day may clinically significantly increase the concentration of drugs metabolized by these pathways. In migraine, this means the necessity of mapping specific interactions before combining CBD with pharmacotherapy.
Triptans with the highest risk of interactions are rizatriptan (metabolized by MAO and CYP2D6), eletriptan (CYP3A4), and almotriptan (CYP3A4). Safer profiles include sumatriptan (extraliver metabolism, excreted by the kidneys) and naratriptan. Practical rule: if you use a triptan acutely 2-3 times a month and CBD at a preventive dose of 40-60 mg, the risk of clinically significant interaction is low. If you use triptans more than 10 days a month, it is still medication overuse headache, and the scheme requires restructuring.
In prevention, three medications require special attention. Topiramate: levels may rise, increasing the risk of paresthesia, weight loss, and cognitive disturbances. Propranolol: increased concentration and risk of bradycardia or hypotension. Amitriptyline: increased concentration and risk of QT interval prolongation. For all these combinations, titration of CBD with constant monitoring of symptoms is recommended, and for amitriptyline, ECG monitoring at doses of CBD above 50 mg per day.
Anti-CGRP antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) are administered subcutaneously or intravenously and do not have hepatic metabolism. This is the safest combination with CBD: no pharmacokinetic interactions, and synergistic action (CBD complements mechanisms that the antibody does not cover). For patients with chronic migraine resistant to classic prevention, the antibody plus CBD 40-80 mg scheme is becoming an increasingly common protocol in European centers.
The most common mistake among customers with migraines is self-combining high doses of CBD (above 100 mg) with amitriptyline or propranolol without consultation. The resulting fatigue, bradycardia, and dizziness are often attributed to CBD, when the actual culprit is the elevated concentration of the classic drug. Solution: either titration of CBD to 40 mg or reduction of classic preventive dosage under medical supervision.
Supporting supplements, namely magnesium, riboflavin, coenzyme Q10
CBD works synergistically with several supplements that have good evidence in migraine. Magnesium (citrate or glycinate, 400-600 mg daily) has strong evidence of effectiveness in the prevention of menstrual and aura-related migraines (Maier et al., Nutrients, 2022). Riboflavin (vitamin B2, 400 mg daily) improves mitochondrial function in neurons, which has been a classic recommendation from migraine specialists since the 1990s.
Coenzyme Q10 (150-300 mg daily) supports the respiratory chain in a complementary way to riboflavin. Melatonin (3-5 mg in the evening) reduces the frequency of attacks in patients with circadian rhythm disorders, which often accompany migraines. CoQ10 and riboflavin safely combine with CBD, as there are no significant pharmacokinetic interactions. Magnesium does not interact but may deepen the feeling of calm after higher doses of CBD, which can be an advantage for those with tension-type migraines.
A rational supplementation stack for chronic migraine looks as follows. Magnesium glycinate 400 mg in the morning, riboflavin 400 mg in the morning with a meal, CoQ10 200 mg with fat for bioavailability, CBD 50-80 mg divided into morning and evening doses, melatonin 3 mg in the evening. This regimen addresses four independent pathophysiological pathways of migraine: magnesium deficiency, mitochondrial dysfunction, endocannabinoid deficiency, and circadian rhythm desynchronization. The monthly cost ranges from 350 to 500 PLN.
What are the side effects of CBD and when not to use it?
The safety profile of CBD is one of the best among substances used in migraine. The report WHO Expert Committee on Drug Dependence (2018) indicates a lack of addictive potential, negligible toxicity, and a low rate of significant adverse effects. In randomized clinical trials, 6-12 percent of participants report mild symptoms, such as fatigue, diarrhea, and changes in appetite.
The most common real issues are drowsiness (especially at doses above 80 mg in the evening), dry mouth, diarrhea (usually resolves after 7-10 days), and transient drops in blood pressure in individuals with baseline hypotension. Less frequently, there is an elevation of liver enzymes (usually at doses above 150 mg, typically asymptomatic). In individuals with chronic migraine and accompanying hepatopathy, it is advisable to monitor ALT and AST every 3 months.
Absolute contraindications include severe liver failure, taking warfarin (risk of bleeding due to interaction with CYP2C9), cannabis allergy, and pregnancy and breastfeeding (lack of long-term data). Relative contraindications: high-dose clobazam, valproate, immunosuppressive drugs metabolized by CYP3A4. Pediatric dosing of CBD in migraine in adolescents is not well established, so the recommendation is to avoid it below the age of 16 or consult a neurologist.
Long-term safety of CBD up to 1500 mg daily in adults is confirmed in reviews, but such doses are not needed in migraine. The range of 30-100 mg covers the vast majority of clinical scenarios, and the risk of serious adverse events in this range is minimal, comparable to placebo in most trials.
When to urgently consult a neurologist?
CBD cannot replace neurological diagnostics. Red flags requiring urgent consultation: the first-ever attack after age 50, 'the worst headache of my life' with sudden onset (thunderclap), pain with fever and neck stiffness, neurological deficit persisting after pain subsides, change in the character of previously stable migraine, headache occurring strictly in the morning with vomiting. These symptoms suggest pathologies other than migraine: subarachnoid hemorrhage, meningitis, brain tumor.
If migraine is chronic (more than 15 days with headache per month for 3 months) or resistant to classic prevention, a referral to a headache clinic provides access to anti-CGRP antibodies, gepants, and newer protocols that CBD cannot replace. A pharmacist or CBD store consultant cannot replace a headache specialist, just as an internist cannot replace a neurologist in difficult clinical scenarios.
Some patients with migraines have comorbid depression, anxiety disorders, or episodes of social phobia. More about this in the text does CBD help in treating depression and CBD and social phobia. In these situations, the neurologist should work together with a psychiatrist, and CBD fits into a common scheme of reducing psychological tension and pain.
What form of CBD is best for migraine?
Sublingual CBD oil (under the tongue) has a bioavailability of 13-19 percent according to Millar et al., Frontiers in Pharmacology (2018). This is twice as much as oral capsules (6-9 percent) and much faster absorption. For an acute attack, this is the preferred form. Onset of action: 15-30 minutes, peak at 90 minutes, duration of action 4-6 hours.
Capsules and oral gels have the advantage of releasing CBD gradually, providing a more stable level in the plasma and a more convenient form for prevention. One 25 mg capsule in the morning, another in the evening, dose without titration of the dropper. The downside is the delay (60-90 minutes to onset of action) and loss of part of the dose due to first-pass hepatic metabolism.
CBD flower for vaporization is an option for chronic migraine with a tension component. Vaporization provides the fastest onset (2-10 minutes) but shorter duration of action (2-3 hours) and higher bioavailability, around 31 percent. It requires a medical vaporizer and dosing discipline. In patients with visual aura or sensitivity to smells, vaporization may be less indicated, as the act of inhalation itself can be a trigger.
Full-spectrum, broad-spectrum, or isolate?
Full-spectrum oil contains CBD plus CBG, CBC, CBN, terpenes, and trace THC up to 0.2 percent. It provides the so-called entourage effect, meaning the interaction of minor cannabinoids and terpenes enhances the main therapeutic effect. In migraine, this is usually the strongest option, but requires caution in THC testing (employment, sports).
Broad-spectrum oil is technologically THC-free but retains terpenes and minor cannabinoids. This is a compromise between efficacy and legal safety, a good choice for professional drivers, athletes, and those regularly tested. Efficacy in migraine is similar to full-spectrum oils, although the entourage effect is somewhat weaker.
CBD isolate is pure cannabidiol (usually 99 percent purity) without other cannabinoids and terpenes. Advantage: lowest cost per milligram of CBD. Disadvantage: lack of entourage effect. In migraine, most data suggest weaker action of the isolate than full-spectrum and broad-spectrum extracts at the same nominal dose of CBD. For those starting out and seeking proof of concept, the isolate can be a reasonable entry point, but it is not the optimal long-term choice.
Do CBG and CBN support migraine therapy?
CBG (cannabigerol) is a precursor to many cannabinoids. It has stronger anti-inflammatory effects than CBD and good evidence in neuropathic pain. In migraine, CBG can complement CBD, especially when the pain has a tension and inflammatory component. Schemes like CBD 10 percent in the morning plus CBG 5 percent in the evening can be rational, but there is a lack of large clinical trials directly comparing such combinations.
CBN (cannabinol) is formed from the oxidation of THC and has sedative effects but without psychoactivity. In migraine, CBN is sometimes used in evening prevention when sleep disturbances are a key trigger for attacks. A dose of 5-10 mg of CBN in the evening combined with 30 mg of CBD is a rational scheme for migraines with pain at dawn and for patients whose insomnia precedes the next attack by several days.
Does CBD work for menstrual migraine, in men and seniors?
Menstrual migraines affect 35-51 percent of women of childbearing age and are exceptionally resistant to classic prevention according to Maasumi et al., The Journal of Headache and Pain (2021). The drop in estrogen around menstruation destabilizes the endocannabinoid system, and this is precisely when exogenous CBD can provide the greatest benefit. Practical scheme: increase the dose by 20-30 percent for 3 days before menstruation and maintain it for 2 days after.
Migraine in men (about 6 percent of the population) is less studied, but available data suggest comparable efficacy of CBD as in women. In this group, chronic migraine with a tension component, work-related stress, and sleep disorders often dominate. A scheme of 40-60 mg of CBD daily combines migraine prevention with stress reduction and sleep improvement, providing three benefits with one preparation, which can be a practical argument for CBD.
In individuals over 60, dosing requires caution. Polypharmacy, increased liver sensitivity, and natural decline in glomerular filtration change pharmacokinetics. A reasonable start is 10 mg once daily, with slow titration to 30-40 mg. An additional benefit is the potential neuroprotective effect of CBD, which in experimental models inhibits neuroinfection and oxidative stress, processes that accelerate migraine and age-related changes.
Individuals with migraine and concomitant depression or anxiety constitute a group in which CBD has a unique advantage. A study Shannon et al., The Permanente Journal (2019) showed that 25-75 mg of CBD daily for 3 months reduces anxiety in 79.2 percent of patients. In combination with migraine, a scheme of 40-80 mg of CBD provides multi-faceted benefits: fewer attacks, less anticipatory anxiety, and better sleep.
Chronic and medication-overuse migraine, or scenarios requiring a special approach
Chronic migraine (more than 15 days with headache per month, including at least 8 with migraine features) affects 1-2 percent of the population. In this group, CBD at a dose of 80-120 mg as an adjunct to classic prevention (topiramate, propranolol, anti-CGRP antibodies) is rational due to the synergistic effect. The expected benefit is a reduction of 3-5 migraine days per month after 12 weeks.
Medication-overuse headache (MOH) develops in individuals overusing acute medications: more than 10 days of triptans per month or more than 15 days of NSAIDs. Treatment requires gradual withdrawal of the overused medication and initiation of prevention. CBD may help in the detox phase, alleviating rebound symptoms, reducing pain, and anticipatory anxiety. This application is off-label but rational mechanistically and supported observationally.
Cluster headache, a rarer but more dramatic form of headache, has less data on CBD. The work of Leroux et al. in The Journal of Headache and Pain (2013) suggested that cannabinoids may interrupt a series of attacks. In practice, some patients with cluster headache report benefits from prevention with full-spectrum oil at a dose of 60-80 mg daily, but further randomized trials are required.
How to choose a good CBD oil for migraine therapy?
The quality of CBD oil directly affects clinical efficacy. According to a review Bonn-Miller et al., JAMA (2017), 69 percent of CBD products available online in the USA had a discrepancy of more than 10 percent between declared and actual CBD content. In Europe, the situation is better, but quality control remains crucial for long-term therapy.
Five criteria for good CBD oil for migraines. First: a certificate of analysis (COA) from an independent laboratory confirming the exact content of CBD, CBG, THC, and absence of contaminants (pesticides, heavy metals, solvents). Second: CO2 extraction at low temperatures, which protects terpenes. Third: carrier oil MCT, hemp, or olive oil (avoid palm and mineral oil). Fourth: dark glass bottle protecting against light. Fifth: extraction date and expiration date on the packaging.
For migraines, specifically rational are full-spectrum or broad-spectrum oils with a predominance of CBD, moderate CBG content (anti-inflammatory), CBC (supporting neurogenesis), trace THC up to 0.2 percent, and high levels of terpenes myrcene (relaxing) and beta-caryophyllene (CB2 agonist, anti-inflammatory). Such compositions mechanistically fit the pathophysiology of migraines, covering more than one pathway at once.
In Polish distribution, reliable producers include CannabiGOLD, HemPoland, SOOL, Cannova, and Essence of Spring. Oils from unverified brands for 40-50 PLN for 10 ml are usually products with contaminants or below the declared CBD content. In migraine, where the dose is clinically significant, a cheaper product with reduced content is not a saving but a waste and a risk.
What will you find in the certificate of analysis (COA)?
COA is a tabular summary that should show: exact content of CBD, CBG, CBC, CBN, and other cannabinoids in mg/ml, content of delta-9-THC (in Poland below 0.2 percent), terpene profile (myrcene, limonene, pinene, beta-caryophyllene), absence of pesticides (glyphosate, chlorpyrifos), heavy metals (lead, cadmium, arsenic, mercury), and residual solvents (ethanol, butane, hexane).
Discrepancies above 10 percent between the label and COA disqualify the product. Lack of COA or outdated document (older than 12 months for a given batch) is a red flag. Manufacturers with the best standards publish COA for each batch on their website and provide the batch number on the bottle, allowing you to verify the exact oil you purchased, not just the general brand label.
How much does monthly CBD therapy for migraine cost and is it worth it?
Cost depends on the chosen dose and concentration of the oil. At a dose of 50 mg daily and 10 percent oil (1000 mg CBD in 10 ml, price 99-200 PLN), the monthly therapy cost is 150-280 PLN. A dose of 100 mg daily doubles this amount. For comparison: monthly therapy with eptinezumab (modern anti-CGRP antibody) costs 2000-2500 PLN, generic topiramate 25 PLN, propranolol 10 PLN, amitriptyline 15 PLN. CBD is positioned in the middle of the price range for classic preventive treatment.
It is worth considering the hidden costs of classic pharmacotherapy. Topiramate requires monitoring of creatinine and body weight, causes weight loss, concentration disturbances (brain fog), and paresthesia. Propranolol controls blood pressure but may cause bradycardia and worsening asthma. Amitriptyline generates weight gain, dry mouth, constipation, and libido disturbances. The cost of absenteeism at work for a patient with chronic migraine is estimated at 9000-15000 PLN annually in Polish conditions.
For episodic migraine (fewer than 15 days with attacks per month), CBD in preventive monotherapy plus triptan as needed is a rational starting point, especially for patients with cardiovascular contraindications to triptans. For resistant chronic migraine, the combination of anti-CGRP antibody plus CBD 40-80 mg provides the best efficacy-to-tolerance ratio, although the total monthly cost is the highest.
5 percent oils (70-90 PLN for 10 ml) are a good entry point. They allow for the first 2-3 months of the so-called trial period without a large expense. After confirming efficacy, migrating to 10-15 percent oils reduces the cost per milligram of CBD by 20-30 percent. For doses above 80 mg daily, 15-20 percent oils are the most economical, although the price threshold for a single bottle is higher.
Contextually, it is worth reading our text how to take CBD, the 4 most popular methods, especially if you are hesitating between oil, capsules, and vaporization. There is also a guide CBD oils, everything you want to know with practical shopping tips.
Frequently Asked Questions
Does CBD really work for migraines?
Available data indicate moderate efficacy. An analysis of 1306 migraine sessions by Cuttler et al. (Journal of Pain, 2020) showed an average reduction in pain intensity of 47.3 percent. The study by Kuhathasan et al. reported relief in 55 percent of patients. The multi-target mechanism (CB1, CB2, TRPV1, 5-HT1A, inhibition of CGRP) fits the pathophysiology of migraines, but there is still a lack of large randomized trials of isolated CBD.
How much CBD to take for migraines?
Start with 10-20 mg daily, increasing every 5-7 days by 10 mg, ultimately aiming for 40-100 mg per day for prevention. In an acute attack, 20-40 mg sublingually, effect in 15-30 minutes. Doses above 150 mg rarely provide additional benefit in migraine and increase the risk of interactions via CYP3A4. Adjust the scheme according to body weight, other medications, and clinical response documented in the headache diary.
Can CBD be combined with triptans?
With caution and in consultation with a neurologist. Safer are sumatriptan and naratriptan (extraliver metabolism), riskier are rizatriptan, eletriptan, and almotriptan (CYP3A4). At doses of CBD up to 40 mg daily and triptan 2-3 times a month, the risk of clinically significant interaction is low. The problem arises with CBD doses of 80-150 mg or frequent use of triptans; then the scheme requires revision and supervision.
How long does it take for CBD to start working on migraines?
In an acute attack, 15-30 minutes (oil under the tongue, bioavailability 13-19 percent according to Millar et al., Frontiers in Pharmacology, 2018). In prevention, the first effects are seen after 3-4 weeks, significant reduction in the number of migraine days usually after 8-12 weeks. This kinetics is comparable to topiramate and propranolol. CBD is not a quick preventive solution, but a multi-month prevention.
Is CBD safe for people with migraine with aura?
Yes, and mechanistic data suggest additional benefit. The work of Greco et al. (Neurotherapeutics, 2020) showed that CB1 and CB2 receptor agonists inhibit cortical spreading depolarization (CSD), the neurophysiological substrate of the aura. In patients with visual aura, preventive 30-60 mg of CBD is associated with a shortening of aura duration and less pain intensity, although hard RCT data on this subgroup are limited.
How does full-spectrum CBD differ from isolate in migraine therapy?
Full-spectrum (full spectrum) contains CBD plus CBG, CBC, CBN, terpenes, and trace THC up to 0.2 percent. It provides the entourage effect and usually stronger analgesic action. Broad-spectrum (broad spectrum) is THC-free but retains terpenes and minor cannabinoids. Isolate is pure CBD without other compounds, cheaper per milligram, but less effective in migraine according to most available clinical data.
When does CBD for migraine not make sense?
In medication-overuse migraine without prior detox, during pregnancy and breastfeeding (lack of long-term safety data), in severe liver failure, when simultaneously taking warfarin (risk of bleeding), in individuals with cannabis allergy. If red flags arise (first attack after age 50, thunderclap, fever and neck stiffness), CBD will not replace urgent neurological diagnostics.
How much does monthly CBD therapy for migraine cost?
At a dose of 50 mg daily and 10 percent oil, the monthly cost is 150-280 PLN. A dose of 100 mg daily doubles this expense. For comparison, generic topiramate costs 25-40 PLN monthly, propranolol 10-20 PLN, and anti-CGRP antibody outside of reimbursement 2000-2500 PLN. CBD is positioned in the middle of the price range for migraine treatment, offering a more tolerant profile than classic preventive medications.
Summary, or is it worth including CBD in migraine treatment?
Yes, in three specific scenarios. First: episodic migraine in patients with cardiovascular contraindications to triptans. Second: chronic migraine with incomplete response to classic prevention, where CBD enters as a component in the scheme with anti-CGRP antibody. Third: menstrual migraine, where estrogen dynamics destabilize the endocannabinoid system. Data from the Journal of Cannabis Research, Journal of Pain, and Neurotherapeutics consistently show clinically significant reductions in pain intensity (averaging 40-55 percent) and moderate reductions in attack frequency.
Key takeaways:
- Multifactorial mechanism: CBD modulates CB1, CB2, TRPV1, and 5-HT1A, raises anandamide, and inhibits CGRP.
- Optimal scheme: 40-100 mg per day in 2-3 doses, titration over 8-12 weeks.
- Acute attack: 20-40 mg sublingually, effect in 15-30 minutes.
- Safety: 6-12 percent mild adverse effects, minimal cardiovascular risk.
- Interactions: caution with rizatriptan, eletriptan, topiramate, propranolol, amitriptyline; absolutely avoid with warfarin.
It is worth reading labels, choosing products with a COA certificate (Certificate of Analysis), treating therapy as a multi-month process, and keeping a headache diary. If you are looking for verified hemp oils, check the category CBD and CBG oils at ubucha.pl, which includes products with analysis certificates and full-spectrum formulations from European hemp.
For a broader clinical context, we also recommend texts on how endocannabinoids alleviate stress, how CBD and THC relieve pain in oncological patients and how cannabis is used in the treatment of acne and skin inflammatory conditions. The pain-relieving and anti-inflammatory mechanisms largely overlap with those used in migraine. It is also worth looking at the article does CBD help with eating disorders, as appetite disorders often accompany migraines as a prodromal symptom.
This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult your doctor, especially if you are taking other medications (including triptans, topiramate, propranolol, amitriptyline, warfarin), are pregnant, breastfeeding, or have liver diseases. Neurological red flags (first seizure after age 50, sudden "worst headache of your life", headache with fever and neck stiffness, neurological deficits after pain subsides) require urgent neurological consultation, not self-supplementation with CBD.
